Clinuvel Pharmaceuticals Ltd:主席致辞
Clinuvel Pharmaceuticals Ltd:加拿大在EPP中提交了SCENESSE的新药申请
Clinuvel Pharmaceuticals Ltd:SCENESSE数据将在全球卟啉病会议上公布
Clinuvel Pharmaceuticals Ltd:股东周年大会会议时间变更
Clinuvel Pharmaceuticals Ltd:董事的首次利息通知-Pearl Grimes
Clinuvel Pharmaceuticals Ltd:董事的初步利息通知-Guy van Dievoet
Clinuvel Pharmaceuticals Ltd:董事的初步利息通知——马修·普林格尔
Clinuvel Pharmaceuticals Ltd:CLINUVEL 投资者网络研讨会
Clinuvel Pharmaceuticals Ltd:公司治理声明
Clinuvel Pharmaceuticals Ltd:附录 4G
Clinuvel Pharmaceuticals Ltd:股息/分配-CUV
Clinuvel Pharmaceuticals Ltd:白癜风和业务更新
Clinuvel Pharmaceuticals Ltd:年度业绩网络研讨会
Clinuvel Pharmaceuticals Ltd:阿法诺肽协助紫外线损伤后的DNA修复反应
Clinuvel Pharmaceuticals Ltd:SCENESSE获得了欧洲治疗孤儿药物认定
Clinuvel Pharmaceuticals Ltd:对于皮肤较浅的帕金森患者,afamelanotide是一种有效的治疗方法。
Clinuvel Pharmaceuticals Ltd:CLINUVEL通讯 III - 2024年6月
Clinuvel Pharmaceuticals Ltd:CLINUVEL 取消了对青少年 EPP 的标签扩展
Clinuvel Pharmaceuticals Ltd:CLINUVEL 和 Valentech 进入拉丁美洲合作伙伴关系
Clinuvel Pharmaceuticals Ltd:SCENESSE XP 欧洲孤儿药认定
暂无数据
暂无数据